Search alternatives:
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
ppm decrease » _ decrease (Expand Search), a decrease (Expand Search), pa decreased (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
Showing 381 - 400 results of 20,502 for search '(( 5 ((ppm decrease) OR (mean decrease)) ) OR ( a ((nn decrease) OR (point decrease)) ))', query time: 0.35s Refine Results
  1. 381
    Metabolite concentrations decrease to near-uninfected levels after treatment of infection.

    Metabolite concentrations decrease to near-uninfected levels after treatment of infection. by Derick N. M. Osakunor (4839597)

    Published 2020
    Save to List
    Saved in:
  2. 382
    The sensitivity analysis results for standardized mean differences of circulating apelin levels between cases with CVDs and controls.

    The sensitivity analysis results for standardized mean differences of circulating apelin levels between cases with CVDs and controls. by Hamed Akbari (8119361)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 383
    Decreased biofilm formation in the Δ<i>tad123</i> mutant cells.

    Decreased biofilm formation in the Δ<i>tad123</i> mutant cells. by Tra-My Duong-Nu (7300970)

    Published 2019
    Save to List
    Saved in:
  4. 384
    Arm tremor and rigidity during settings (mean ± sd).

    Arm tremor and rigidity during settings (mean ± sd). by Verneri Ruonala (12419145)

    Published 2022
    Save to List
    Saved in:
  5. 385
    Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups.

    Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups. by Cristina Dolciotti (16317330)

    Published 2025
    Save to List
    Saved in:
  6. 386
    Overtrained mice show dichotomous modulation of timing-dependent synaptic depression (tLTD) in response to a change in the prevailing A–O contingency.

    Overtrained mice show dichotomous modulation of timing-dependent synaptic depression (tLTD) in response to a change in the prevailing A–O contingency. by Vincent Paget-Blanc (21807763)

    Published 2025
    Save to List
    Saved in:
  7. 387
    Efficacy end points.

    Efficacy end points. by Youngmin Ko (3333819)

    Published 2023
    Save to List
    Saved in:
  8. 388
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 389
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 390
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 391
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 392
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 393
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 394
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 395
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 396
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 397
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 398
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 399
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 400
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: